Mathir Z M, Dangor C M, Govender T, Chetty D J
Pharmacy Department, University of Durban-Westville, South Africa.
J Microencapsul. 1997 Nov-Dec;14(6):743-51. doi: 10.3109/02652049709006824.
Non-pareil cores were spray-coated with a chlorpheniramine maleate (an alkylamine antihistamine) layer and a Eudragit NE30D overcoat in a Wurster air-suspension apparatus. In vitro dissolution studies demonstrated that drug release was a function of polymer membrane thickness. Polyethylene glycol 6000, as a hydrophillic additive, increased the in vitro release of chlorpheniramine maleate from the pellets. Pellets coated with 8.30% Eudragit NE30D, 0.50% talc and 1.00% polyethylene glycol 6000 were found to display desirable controlled release characteristics for chlorpheniramine maleate over the 8-h testing period, which were also comparable with that of Dykatuss capsules. The controlled release pellets exhibited first-order release characteristics for chlorpheniramine maleate. Reproducibility of the manufacturing conditions employed in the study were confirmed thus ensuring reproducibility of drug release characteristics between batches of chlorpheniramine maleate pellets. Drug release from the pellets was shown to be independent of the dissolution method and medium used. Pellets displayed no significant change in drug release characteristics relative to the initial drug release data when stored for 12 weeks at room temperature (20 +/- 2 degrees C) and for 8 weeks at a low temperature (5 +/- 1 degrees C). However, pellets stored at 37 degrees C with 80% relative humidity and at 40 +/- 2 degrees C showed a slower in vitro drug release after 8-week storage and therefore failed to maintain their initial drug release profile.
在Wurster空气悬浮装置中,将无与伦比核芯用马来酸氯苯那敏(一种烷基胺抗组胺药)层和Eudragit NE30D外涂层进行喷雾包衣。体外溶出度研究表明,药物释放是聚合物膜厚度的函数。聚乙二醇6000作为亲水性添加剂,增加了马来酸氯苯那敏从微丸中的体外释放。发现包衣有8.30% Eudragit NE30D、0.50%滑石粉和1.00%聚乙二醇6000的微丸在8小时测试期内对马来酸氯苯那敏显示出理想的控释特性,这也与Dykatuss胶囊的控释特性相当。控释微丸对马来酸氯苯那敏表现出一级释放特性。因此证实了该研究中所采用制造条件的可重复性,确保了不同批次马来酸氯苯那敏微丸之间药物释放特性的可重复性。微丸的药物释放显示与所用的溶出方法和介质无关。当在室温(20±2℃)下储存12周和在低温(5±1℃)下储存8周时,微丸的药物释放特性相对于初始药物释放数据没有显著变化。然而,在37℃和80%相对湿度下以及在40±2℃下储存的微丸在储存8周后显示出较慢的体外药物释放,因此未能维持其初始药物释放曲线。